Get started
Author

Vladimir Galvao

Observed names: V. Galvao, V. Galvão, Vladimir Galvão
ORCID: 0009-0007-8139-8215
Observed ORCID: 0009-0007-8139-8215
OpenAlex ID: A5037161571
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
2025 · Juanita Lopez, Thomas Powles, et al. · Nature Medicine · 118
PDF
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023 · Maria Vieito, Victor Moreno, et al. · Clinical Cancer Research · 86
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
2023 · Victor Moreno, Maria Vieito, et al. · Nature Communications · 25
PDF
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025 · Valentina Gambardella, Michael Ong, et al. · Cancer Research Communications · 19
PDF
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
2023 · Antoine Hollebecque, Juanita Suzanne Lopez, et al. · Journal of Clinical Oncology · 17
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis
2025 · S. Martín-Lluesma, U. Dafni, et al. · Annals of Oncology · 13
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
2022 · Elena Garralda, Aung Naing, et al. · Journal of Clinical Oncology · 13
Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).
2024 · Solange Peters, Antoine Hollebecque, et al. · Journal of Clinical Oncology · 12
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors
2024 · Macarena Román Alonso, Ariadna Grinyó-Escuer, et al. · Nature Communications · 9
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
2025 · Elena Garralda, Charles Abbott, et al. · Clinical Cancer Research · 7
PDF
494 Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas
2021 · Melissa Johnson, Lilian Siu, et al. · Regular and Young Investigator Award Abstracts · 7
PDF
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
2021 · Ignacio Matos, Guillermo Villacampa, et al. · European Journal of Cancer · 7
PDF
A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).
2021 · Amita Patnaik, Emiliano Calvo, et al. · Journal of Clinical Oncology · 7
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
2025 · Stephane Champiat, Elena Garralda, et al. · Cell Reports Medicine · 6
Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancers
2024 · J. Palomero, V. Galvao, et al. · Immuno-Oncology Technology · 5
Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.
2024 · Rodrigo De Almeida Toledo, Alma M Calahorro García, et al. · Journal of Clinical Oncology · 5
EVICTION study: ICT01, an anti-Butyrophilin 3A monoclonal antibody activating γ9δ2 T cells in combination with pembrolizumab in checkpoint inhibitor refractory melanoma.
2024 · Stephane Champiat, Martin Wermke, et al. · Journal of Clinical Oncology · 5
PDF
525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors
2021 · Stefan Symeonides, Devalingam Mahalingam, et al. · Regular and Young Investigator Award Abstracts · 4
PDF
Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT).
2021 · Omar Saavedra Santa Gadea, Alberto Hernando-Calvo, et al. · Journal of Clinical Oncology · 4
Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.
2025 · Aung Naing, Khaldoun Almhanna, et al. · Journal of Clinical Oncology · 3
PDF
731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001)
2022 · Antoine Hollebecque, Juanita Lopez, et al. · Regular and Young Investigator Award Abstracts · 3
PDF
Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial
2022 · Stephane Champiat, Aurelien Marabelle, et al. · Cancer Research · 3
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer
2026 · Solange Peters, Sarina A. Piha-Paul, et al. · Journal of Clinical Oncology · 2
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma
2025 · Melissa Johnson, David Hong, et al. · Investigational New Drugs · 2
1048P Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer
2023 · N. Kotecki, S. Rottey, et al. · Annals of Oncology · 2
PDF
Works count: 92
Citation count: 395
H-index: 9
I10-index: 8
Year
Topic
Type